CAR-T therapy for children with B-cell ALL needing transplant
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new type of immune-cell therapy (called CAR-T cells) for children and young adults with a specific blood cancer (B-cell ALL) who need a stem cell transplant. The treatment uses a patient's own T-cells that are modified to find and kill cancer cells with the CD19 marker.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child is under 25 years old.
- Diagnosed with CD19-positive B-cell acute lymphoblastic leukemia (a type of blood cancer where cancer cells have the CD19 protein).
- The leukemia is in remission (less than 5% cancer cells in the bone marrow) after the first or second round of chemotherapy.
- You must be considered eligible for a stem cell transplant (for example, due to certain gene changes, detection of minimal residual disease, failure of first treatment, or your doctor's judgment).
- You have not already had a stem cell transplant.
- You do not have an active uncontrolled infection, and are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a homemade (hospital-manufactured) immune treatment called CD19 CAR-T for children and teens with a type of leukemia that has come back or did not respond. It may help by targeting leukemia cells that carry the CD19 marker.
This trial tests a CD19-targeted CAR-T cell therapy (S1904) for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. After CAR-T, some patients may go on to a stem cell transplant. The goal is to see if the CAR-T can lead to remission and who needs a transplant.
This trial tests a special immune cell treatment (CAR-T cells) for children whose leukemia or lymphoma has come back or not responded to at least two prior treatments. The goal is to see if these cells can find and destroy the cancer.
This trial tests a new treatment using the patient's own immune cells, modified to find and attack leukemia cells that remain after initial chemotherapy. It's for children with B-cell acute lymphoblastic leukemia who still have tiny amounts of cancer cells detectable after standard treatment.
This trial tests a new CAR T cell treatment for children whose B-cell acute lymphoblastic leukemia has come back or not responded to standard therapy. The goal is to see if this therapy is safe and can help control the cancer so a stem cell transplant may be possible.
This trial tests a new type of immunotherapy called CAR-T-19 for children and young adults up to age 25 whose B-ALL has returned or is not responding to standard treatments. The CAR-T cells are engineered to find and destroy leukemia cells that have the CD19 protein.
Hear when a new Very High Risk Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.